Biotech entity
Every one of those 1 sits in a single category, pharma. Skyclarys is most often covered alongside European Union, which appears in 1 of these 1 story. Skyclarys appears in 1 tracked Biotech story from August 16, 2026. The tracked stories average 2 original sources each.
Last mentioned: Aug 16, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Skyclarys is most often covered alongside European Union, which appears in 1 of these 1 story. Skyclarys appears in 1 tracked Biotech story from August 16, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Skyclarys. Shared-story counts are live from our verified record — not editorial picks.
For biopharma, Ireland's HSE Drugs Group non-recommendation for Skyclarys highlights the mounting gap between EMA approval and national reimbursement in rare diseases. The decision, citing evidence limitations and price, leaves around 200 Irish patients without public access despite EU-wide authorization since February 2024.
Source: zimbabwestar.com · floridastatesman.com
Skyclarys is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
